Cost-effectiveness and costutility analysis of Deprexis®, a digital therapy intended for the treatment of mild to severe depression, in Catalonia
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Rothe Muñoz, Rainer Mariano
- dc.date.accessioned 2022-02-14T09:47:32Z
- dc.date.available 2022-02-14T09:47:32Z
- dc.date.issued 2021
- dc.description Master in Health Economics and Pharmacoeconomics. UPF Barcelona School of Managementeng
- dc.description Mentor: Laura Vallejospa
- dc.description.abstract Depression is an illness that has a strong social and economic impact, and that has seen its prevalence increased during the COVID-19 pandemic. As with many sectors of healthcare, the increased costs of treatment and the scarce availability of professionals lead to long waiting lists, generating a need for digital innovation in the management of depression. Deprexis® is a digital therapy that has been recently approved for its reimbursement under prescription in Germany and that has been studied for its efficacy in the treatment of depression as a complement of care-as-usual, as a partial replacement of care-as-usual (CAU) and as a tool to be used in patients in waiting list. In this study the incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratios (ICUR) of the introduction of Deprexis® as a complement of CAU for the treatment of depression in the region of Catalonia and from the perspective of both, society, and that of the National Health Service, were estimated using a Markov model. It was found that, when compared with CAU, the introduction of Deprexis® incurred an ICER of 3,866 € per clinically improved individual over a one-year time horizon and a ICUR of 125,498 € per quality adjusted life year from the perspective of the National Health service, and 2,248 € per clinically improved individual and 72,970 € per QALY from the societal perspectiveca
- dc.format.mimetype application/pdfspa
- dc.identifier.uri http://hdl.handle.net/10230/52485
- dc.language eng
- dc.language.iso engca
- dc.rights.accessRights info:eu-repo/semantics/openAccessca
- dc.subject.keyword cost-effectivenesseng
- dc.subject.keyword cost-utility
- dc.subject.keyword COVID-19eng
- dc.subject.keyword depressioneng
- dc.subject.keyword digital healtheng
- dc.subject.keyword Markov modeleng
- dc.subject.other Treball de fi de màster – Curs 2020-2021ca
- dc.title Cost-effectiveness and costutility analysis of Deprexis®, a digital therapy intended for the treatment of mild to severe depression, in Cataloniaca
- dc.type info:eu-repo/semantics/masterThesisca